SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Alembic Pharmaceuticals informs about press release

20 Feb 2019 Evaluate

Alembic Pharmaceuticals has informed that the Company has received US Food & Drug Administration (USFDA) Approval for Acetazolamide Extended-Release Capsules, 500 mg. Further, the company has submitted its press release.

The above information is a part of company’s filings submitted to BSE.

Alembic Pharma Share Price

772.00 -12.95 (-1.65%)
20-Apr-2026 09:43 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1676.00
Dr. Reddys Lab 1235.40
Cipla 1235.05
Zydus Lifesciences 941.20
Lupin 2330.65
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×